Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Yuan Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0449-1356; OpenAlex author ID A5101464119. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: 3 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 12

  1. Long non-coding RNAs in pancreatic cancer. Co-author DOI 10.1016/j.cca.2024.120040↗
  2. Enhanced cytokine signaling and ferroptosis defense interplay initiates obesity-associated pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2024.217162↗
  3. Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer. First author DOI 10.1097/jp9.0000000000000175↗
  4. Cell-in-Cell-Mediated Entosis Reveals a Progressive Mechanism in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.08.035↗
  5. A commentary on 'The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study'. Co-author DOI 10.1097/js9.0000000000000588↗
  6. Lipid metabolism in pancreatic cancer: emerging roles and potential targets. Co-author DOI 10.1002/cac2.12360↗
  7. Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. First author DOI 10.1186/s12885-022-09927-0↗
  8. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in … Co-author DOI 10.1186/s12885-022-09983-6↗
  9. Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. Co-author DOI 10.1186/s12935-021-01928-6↗
  10. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. Co-author DOI 10.1186/s13045-021-01131-0↗
  11. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2021.758004↗
  12. Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. Co-author DOI 10.3389/fonc.2020.572722↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yupei Zhao · 10 shared papers, 2020–2024 · strength 1.81
  2. Ruiyuan Xu · 10 shared papers, 2020–2024 · strength 1.68
  3. Jianlu Song · 8 shared papers, 2021–2024 · strength 1.44
  4. Rexiati Ruze · 8 shared papers, 2021–2024 · strength 1.44
  5. Xinpeng Yin · 6 shared papers, 2022–2024 · strength 1.14
  6. Chengcheng Wang · 4 shared papers, 2021–2024 · strength 0.83
  7. Jinshou Yang · 3 shared papers, 2020–2021 · strength 0.38
  8. Lei You · 3 shared papers, 2020–2021 · strength 0.38
  9. Chengcheng Wang · 2 shared papers, 2022–2023 · strength 0.35
  10. Qiang Xu · 2 shared papers, 2022 · strength 0.33
  11. Jin Ding · 1 shared paper, 2025 · strength 0.33
  12. Chengcheng Wang · 2 shared papers, 2021 · strength 0.28
  13. Bo Ren · 2 shared papers, 2020–2021 · strength 0.24
  14. Gang Yang · 2 shared papers, 2020–2021 · strength 0.24
  15. Chengcheng Wang · 1 shared paper, 2024 · strength 0.23
  16. Hui Zhang · 1 shared paper, 2023 · strength 0.18
  17. Qiang Xu · 1 shared paper, 2022 · strength 0.17
  18. Taiping Zhang · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.